RecruitingNot Applicable

Minimal Vitrectomy Surgery for Epiretinal Membrane

China140 participantsStarted 2024-12-01

Plain-language summary

This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years.
✓. Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
✓. Clear ocular media allowing adequate fundus imaging.
✓. Phakic eye.
✓. Ability and willingness to provide written informed consent.

Exclusion criteria

✕. Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
✕. Systemic conditions preventing safe surgery or follow-up.
✕. History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.

What they're measuring

Cataract progression assessed by LOCS III and DLI

Timeframe: Baseline, 12 months

Trial details

NCT IDNCT07019896

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11-30

Contact for this trial

Weihong Yu, MD

+8613671214306 yuweihongpumch@163.com

View on ClinicalTrials.gov More Epiretinal Membrane trials